Hepatitis

  • Most Topular Stories

  • Mechanism helps explain persistence of hepatitis C virus

    Liver Disease / Hepatitis News From Medical News Today
    18 Apr 2014 | 12:00 am
    Researchers at the University of California, San Diego School of Medicine have identified a mechanism that explains why people with the hepatitis C virus get liver disease and why the virus is able...
  • Gilead’s Hepatitis C pill patent debate in India, concerns about access to breakthrough drug

    HCV New Drug Research
    21 Apr 2014 | 11:22 am
    Amidst Gilead’s Hepatitis C pill patent debate in India, concerns about access to breakthrough drugApril 21, 2014 10:42 am by Stephanie LeeGilead has run into obstacles in China, which yanked the patent for its HIV and hepatitis B drug last year because the treatment lacked novelty, officials said. Brazil rejected that drug's patent in 2008. Thailand has broken patents on drugs for HIV and heart disease, and so has Indonesia for HIV and hepatitis B treatments. Those drugs attracted attention because they treat widespread diseases. In India, an estimated 12 million people have hepatitis…
  • Key Findings About HCV Genotype 3

    Hepatitis Central
    The Editors at Hepatitis Central
    22 Apr 2014 | 7:13 am
    Regimens Containing Gilead’s Sovaldi Have Major Advantages over Other Therapies for Hepatitis C Virus Genotype-3 Gastroenterologists Would Prescribe Sovaldi plus Daclatasvir plus Ribavirin to 60 Percent of Their Genotype-3 Patients, According to Findings from Decision Resources Group PR Newswire BURLINGTON, Mass., April 1, 2014 /PRNewswire/ — Decision Resources Group finds that surveyed gastroenterologists in the United States and Europe agree that the percentage of hepatitis C virus (HCV) genotype-3 infected patients with cirrhosis of the liver achieving a sustained virologic…
  • How Healthy is Your Liver?

    About.com Hepatitis: Most Popular Articles
    22 Apr 2014 | 4:51 am
    Liver enzymes allow doctors to learn about the health of your liver. There are thousands of these enzymes in the liver and blood stream, but two of them--two aminotransferases--are especially useful for determining liver disease: AST and ALT.
  • Economic Evaluation of the Routine Childhood Immunization Program in the United States, 2009

    MedWorm: Hepatitis B
    31 Mar 2014 | 4:00 pm
    CONCLUSIONS: From both direct cost and societal perspectives, vaccinating children as recommended with these vaccines results in substantial cost savings. (Source: PEDIATRICS)MedWorm Sponsor Message: Find the best Christmas Sales, Boxing Day Sales and January Sales here.
 
  • add this feed to my.Alltop

    About.com Hepatitis: What's Hot Now

  • Will You Need a Liver Transplant?

    hepatitis.guide@about.com
    22 Apr 2014 | 4:07 am
    Liver transplantation is the best treatment for some patients with acute or chronic liver disease that is progressive and life-threatening.
  • Hepatitis B Virus Infection

    hepatitis.guide@about.com
    22 Apr 2014 | 4:07 am
    Hepatitis B is a disease caused by the hepatitis B virus, and can be acute or chronic. Infection with hepatitis B virus is the leading cause of chronic hepatitis worldwide and people with chronic hepatitis B infection are at increased risk for developing liver cancer. In addition, the hepatitis B virus is the leading cause of cirrhosis in the world.
  • Can I Donate Blood if I Have Hepatitis?

    hepatitis.guide@about.com
    22 Apr 2014 | 4:07 am
    If you had any kind of viral hepatitis, or unexplained jaundice, at any time since you were age 11, you're not able to donate blood.
  • What It Means if Your Doctor Orders an HBsAG Test

    hepatitis.guide@about.com
    22 Apr 2014 | 4:07 am
    Definition of HBsAG. Hepatitis.
  • The Stomach

    hepatitis.guide@about.com
    22 Apr 2014 | 4:07 am
    Hepatitis. Page 4.
 
  • add this feed to my.Alltop

    Hepatitis Central

  • Key Findings About HCV Genotype 3

    The Editors at Hepatitis Central
    22 Apr 2014 | 7:13 am
    Regimens Containing Gilead’s Sovaldi Have Major Advantages over Other Therapies for Hepatitis C Virus Genotype-3 Gastroenterologists Would Prescribe Sovaldi plus Daclatasvir plus Ribavirin to 60 Percent of Their Genotype-3 Patients, According to Findings from Decision Resources Group PR Newswire BURLINGTON, Mass., April 1, 2014 /PRNewswire/ — Decision Resources Group finds that surveyed gastroenterologists in the United States and Europe agree that the percentage of hepatitis C virus (HCV) genotype-3 infected patients with cirrhosis of the liver achieving a sustained virologic…
  • Diet Supplement Tied to Hepatitis

    Nicole Cutler L.Ac.
    21 Apr 2014 | 1:51 pm
    A diet supplement claiming to burn fat, OxyElite Pro, is no longer on the market because of its connection with nearly 100 cases of hepatitis. This startling statistic highlights the urgent need for two important changes: improved oversight of nutritional products and greater support for healthful weight loss. Obesity Generally equivalent to a person’s percentage of body fat, body mass index (BMI) greater than 30 is considered obese. Obesity has been linked to a majority of preventable diseases that can result in serious illness or death. Affecting at least a third of Americans, obesity…
  • New Hepatitis C Study Cures 90% of Patients

    The Editors at Hepatitis Central
    11 Apr 2014 | 7:25 am
    Bristol-Myers hepatitis C treatment cures up to 90 percent in new study Published April 10, 2014 Reuters A combination of two anti-viral drugs developed by Bristol-Myers Squibb Co cured 90 percent of previously untreated hepatitis C patients and 82 percent of those who failed to respond to prior therapy, according to results from a late stage study presented on Thursday. The Phase III trial of more than 700 patients called Hallmark-Dual tested a combination of Bristol’s daclatasvir and asunaprevir over 24 weeks of therapy in patients with genotype 1b of the virus that causes progressive…
  • FREE Educational Webinar: What You Need to Know About HCV

    The Editors at Hepatitis Central
    7 Apr 2014 | 8:48 am
    A Discussion on HEPATITIS C: What You Need to Know When: Wednesday, April 23rd at 7pm. How to Register: http://meetthehcvexpert.com/Dieterich/registration.cfm?CFID=5439845&CFTOKEN=99387613
  • FREE WEBINAR Diagnosing and Treating HE: A Physician’s Perspective

    The Editors at Hepatitis Central
    7 Apr 2014 | 8:39 am
    The American Liver Foundation invites you to participateinthe second of a four-part series of live webinars on hepatic encephalopathy (HE) to be held Wednesday, April 23, 2014. The program, Diagnosing and Treating HE: A Physician’s Perspective, isdesigned for patients and caregivers who need a better grasp of this complicated condition or want a clearer understanding about a specific HE-related issue. HE is most often seen in people with chronic liver disease. It’s a major complication of cirrhosis – whether caused by viral hepatitis, fatty liver disease or long-term alcohol use. …
 
 
  • add this feed to my.Alltop

    Hepatitis Blog

  • Hepatitis A Week: Charlotte, North Carolina Papa John’s and Nyack, New York La Fontana

    Bill Marler
    12 Apr 2014 | 8:49 am
    Charlotte North Carolina: A Papa John’s outlet is to blame for a Hepatitis A scare, according to the Mecklenburg County Health Department. Anyone who ate food from the location on March 28 and 29 should get the Hepatitis A vaccine immediately. Officials are looking into a potential Hepatitis A outbreak from the Papa John’s location in the 8000 block of Cambridge Commons in Charlotte, near Harrisburg Road and I-485. According to the health department, a manager at that restaurant, who recently traveled out of the country, contracted Hepatitis A and may have infected Papa John’s patrons.
  • 28 with Hepatitis A in Norway

    Bill Marler
    30 Mar 2014 | 3:58 pm
    A total of 28 cases of hepatitis A infection have been reported over the last few months in Norway, where this disease is said to be rare, local health officials said. Health authorities, who were worried by the growing number of hepatitis A cases, are working to determine whether the sick people are infected from a common source. In almost half of the cases, the patients were found to have infected with hepatitis A virus while traveling abroad, The remaining half got infected in Norway, which was described as a rare occurrence. Infection of hepatitis A virus can also occur through person to…
  • New Zealand Apples and Peaches Recalled Over Hepatitis A Exposure

    Bill Marler
    16 Mar 2014 | 8:57 pm
    The Ministry for Primary Industries (MPI) is cautioning New Zealand consumers of a small quantity of fresh fruit sold in late February and early March that there is a relatively low risk that this fruit had been contaminated with Hepatitis A virus. MPI Deputy Director General Scott Gallacher says it is important that consumers understand the risk of transmission of the virus is relatively low, but MPI is issuing this information as a precaution so that people with any related concerns about their health can contact their doctor. “As always, MPI is placing the health and wellbeing of all…
  • Hepatitis A Vaccines Reccomended After Hilton Head Exposure

    Bill Marler
    26 Feb 2014 | 4:24 am
    The Hilton Head Island Packet reports that nearly 300 people might have been exposed to hepatitis A at Hudson’s Seafood House on the Docks restaurant February 15th, but so far no cases stemming from the exposure have been confirmed.  An employee at Hudson’s Seafood House on the Docks tested positive for hepatitis A on last Friday, six days after the employee had worked at the restaurant. Anyone who was at the restaurant from 4 p.m. until closing time February 15th — when the infected employee was working — should contact his or her primary care provider to receive a…
  • Hudson’s Seafood House Employee with Hepatitis A

    Bill Marler
    23 Feb 2014 | 2:18 am
    According to the South Carolina Department of Health and Environmental Control (DHEC), customers and staff of Hudson’s Seafood House on the Docks in Hilton Head Island who were present at the restaurant on the evening of February 15, 2014, are encouraged to contact their primary care provider to receive treatment for possible exposure to the Hepatitis A virus.  On Friday, DHEC was notified that an employee who worked at the restaurant on the evening of February 15 has tested positive for Hepatitis A. The employee is being treated for the infection and has not returned to work. Exposure…
  • add this feed to my.Alltop

    HCV Support

  • Complete Coverage of EASL 2014

    22 Apr 2014 | 12:57 pm
    http://207.56.172.200/HIVandHepatitis/EASL2014.html
  • Re: Emergency In Egypt

    22 Apr 2014 | 12:49 pm
    Thank you Alex 
  • Emergency In Egypt

    21 Apr 2014 | 11:19 am
    I had my 12 week check up tonight and Dr informed  me he had just returned from HCV meetings in Europe and talked about the fact new drugs will not be approved there for some time to come.....In addition, he stated that as of now HCV rate in Egypt has ...
  • Specialty Drug Prices spark concerns

    20 Apr 2014 | 10:24 pm
    From The NewYorker magazine:http://www.newyorker.com/talk/financial/2014/04/28/140428ta_talk_surowiecki
  • Hepatitis C spiking on Cape

    20 Apr 2014 | 7:41 am
    http://www.capecodonline.com/apps/pbcs.dll/article?AID=/20140420/NEWS/404200338
  • add this feed to my.Alltop

    HCV New Drug Research

  • AbbVie, Enanta’s collaboration partner for ABT-450, has submitted (NDA) to the FDA for interferon-free regimen

    22 Apr 2014 | 6:42 am
    Investment Commentary AbbVie heads to the FDA with its hep C combo in a race with Gilead, MerckApril 22, 2014 | By Damian Garde AbbVie ($ABBV) has submitted an FDA application for its promising all-oral hepatitis C treatment, expecting approval this year as it prepares for a three-way race with perceived leaders Gilead Sciences ($GILD) and Merck ($MRK).......Press ReleaseEnanta Pharmaceuticals Announces New Drug Application Submission to the U.S. FDA for All-Oral, Interferon-Free Hepatitis C Regimen Filing Triggers Milestone Payment to EnantaAbbVie’s submission to FDA triggers $20…
  • Advances in Chronic Hepatitis C Management and Treatment - EASL 1.5-hour Internet symposium

    21 Apr 2014 | 4:46 pm
    When new education-related information on hepatitis is released online this blog provides background information and links to the new activity.    ViralEd just released an 1.5-hour Internet symposium discussing key data presented at the 49th Annual Meeting of the European Association for the Study of the Liver (49th EASL) which took place this month in London, England.Advances in Chronic Hepatitis C Management and Treatment Highlights HCV Therapies In Treatment Naive PatientsHCV Therapies In Treatment Experienced Patients  Studies In HIV/HCV Co-Infection and Other Public…
  • Gilead’s Hepatitis C pill patent debate in India, concerns about access to breakthrough drug

    21 Apr 2014 | 11:22 am
    Amidst Gilead’s Hepatitis C pill patent debate in India, concerns about access to breakthrough drugApril 21, 2014 10:42 am by Stephanie LeeGilead has run into obstacles in China, which yanked the patent for its HIV and hepatitis B drug last year because the treatment lacked novelty, officials said. Brazil rejected that drug's patent in 2008. Thailand has broken patents on drugs for HIV and heart disease, and so has Indonesia for HIV and hepatitis B treatments. Those drugs attracted attention because they treat widespread diseases. In India, an estimated 12 million people have hepatitis…
  • HCV Next - A Conversation with Douglas T. Dieterich, MD

    21 Apr 2014 | 5:30 am
    The following articles appeared in the March/April 2014 print edition of  HCV Next at Healio.EditorialIntroducing our Chief Medical Editors
In this issue, you will read an in-depth cover story with expert opinion on the controversial costs of care surrounding implementation of the new approved direct-acting antiviral therapies. The feature article explores the debate between risk-based and universal HCV screening recommendations for baby boomers. HCV Next Editorial Board member Catherine T. Frenette, MD, and colleagues present an interesting Case Challenge about a patient with unique…
  • Behind The Headlines - New hepatitis C drug treatment 'shows promise'

    18 Apr 2014 | 4:34 am
     What is Behind the Headlines?Each day the NHS Choices team selects health stories that are making headlines. These, along with the scientific articles behind the stories, are sent to Bazian, a leading provider of evidence-based healthcare information. Bazian's clinicians and scientists analyse the research and produce impartial evidence-based assessments, which are edited and published by NHS Choices.Read more about the production process. New hepatitis C drug treatment 'shows promise'"A new treatment for hepatitis C 'cured' 90% of patients with the infection in 12 weeks,…
 
Log in